GlassScriptPhysician profile
John W Interlandi
NPI 1992790174
$4,601.83
in general payments reported to CMS, 2019-2025
25 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $1,095 · 2021: $1,904 · 2022: $328 · 2023: $557 · 2024: $182 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $2,048.94 | 2019-2022 | |
| Becton, Dickinson and Company | $495.00 | 2021 | |
| Corcept Therapeutics | $330.44 | 2023-2025 | Korlym |
| Abbott Laboratories | $263.54 | 2020-2022 | |
| Beta Bionics, INC. | $256.15 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $247.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $183.38 | 2019-2024 | Farxiga |
| Zealand Pharma US, INC. | $136.70 | 2021 | |
| Novo Nordisk INC | $99.66 | 2019-2025 | Wegovy |
| Valeritas, INC. | $98.87 | 2019 | |
| Horizon Therapeutics Plc | $83.42 | 2020-2021 | |
| Amgen INC. | $54.42 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $40.18 | 2023 | |
| Sanofi-Aventis U.S. LLC | $30.36 | 2020-2022 | |
| Dexcom, INC. | $30.22 | 2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $26.55 | 2025 | Senza |
| Lilly USA, LLC | $25.60 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $24.70 | 2025 | Unithroid |
| Biohaven Pharmaceutical Holding Company LTD. | $22.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.74 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $19.21 | 2022 | |
| Madrigal Pharmaceuticals | $17.32 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.93 | 2020 | |
| Medtronic, INC. | $15.72 | 2023 | Minimed 780g |
| Amarin Pharma, INC. | $14.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Interlandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.